Clinical Trials Logo

Peripheral T-cell Lymphoma clinical trials

View clinical trials related to Peripheral T-cell Lymphoma.

Filter by:

NCT ID: NCT01839916 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: April 4, 2013
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

NCT ID: NCT01839097 Completed - Clinical trials for Peripheral T-cell Lymphoma

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Start date: May 2013
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.

NCT ID: NCT01822886 Completed - Clinical trials for Peripheral T-cell Lymphoma

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

FIL_GEMRO
Start date: January 2013
Phase: Phase 2
Study type: Interventional

Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma) in a selected population of patients.

NCT ID: NCT01806337 Completed - Clinical trials for Peripheral T-Cell Lymphoma

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation

NCT ID: NCT01796002 Completed - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: January 2013
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).

NCT ID: NCT01767766 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Start date: January 7, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.

NCT ID: NCT01748721 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Start date: November 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them

NCT ID: NCT01716806 Completed - Hodgkin Disease Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Start date: October 31, 2012
Phase: Phase 2
Study type: Interventional

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.

NCT ID: NCT01689220 Completed - Clinical trials for Peripheral T-cell Lymphoma

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Start date: September 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).

NCT ID: NCT01658319 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Start date: May 2011
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of methoxyamine when given together with fludarabine phosphate in treating patients with relapsed or refractory hematologic malignancies. Drugs used in chemotherapy, such as methoxyamine and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with fludarabine phosphate may kill more cancer cells.